HK40080024A - Composition containing lactic acid bacteria - Google Patents

Description

Composition containing lactic acid bacteria

Technical Field

The present invention relates to a composition containing lactic acid bacteria having an antiallergic effect.

Background

Allergic diseases control their onset through the interaction of various factors such as genetic factors, environmental factors (e.g., infant birth environment, intestinal flora, etc.).

It is considered that intestinal bacteria affect the development of the immune system of a host (non-patent document 1), and examples of intestinal bacteria having a certain relationship with allergic diseases include lactic acid bacteria. In addition, it has been reported that the environment where a pet lives during infancy is important as an environmental factor of allergic diseases, and for example, the allergic attack can be suppressed by microbial crosstalk between humans and pets caused by contact with pets (dogs, cats, etc.) during infancy (non-patent documents 2 and 3). Fujimura et al reported that the ratio of Lactobacillus Johnsonii (Lactobacillus Johnsonii) as a lactic acid bacterium in the intestinal flora of mice exposed to house dust in an environment where dogs were raised was significantly increased, and Lactobacillus Johnsonii exerted an important role in inhibiting allergic respiratory diseases (non-patent document 4).

On the other hand, taylor et al administered Lactobacillus acidophilus (Lactobacillus acidophilus) to infants born to mothers with allergic diseases until 6 months after birth to analyze the effect of Lactobacillus on the onset of allergy, and the results showed that there was no significant difference in the incidence of atopic dermatitis between the administered group and the placebo administered group at the time of 1 year after birth, and the positive rate of IgE antibody was high in the Lactobacillus acidophilus administered group (non-patent document 5).

As described above, although lactic acid bacteria have a certain effect on allergic diseases, they show the opposite results (negative results in non-patent document 5 and positive results in non-patent document 4), and it is necessary to further analyze which species are more effective and practical for suppressing allergy.

Documents of the prior art

Non-patent document

Non-patent document 1: macphers and Harris, nat Rev Immunol.4:478-485 2004.

Non-patent document 2: hesselmar et al, clin Exp allergy.29:611-617 1999.

Non-patent document 3: fall et al, JAMA Peditar.1699 e153219 2015

Non-patent document 4: fujimura et al, proc Natl Aca Sci USA 14.

Non-patent document 5: tylor et al, J Allergy Clin Immuno.119:184-191 2007.

Disclosure of Invention

In view of the above, an object of the present invention is to provide a composition containing lactic acid bacteria effective for suppressing the onset of allergy.

The present inventors considered that enteric bacteria of dogs have some influence on the immune system of the host, and compared the intestinal flora of healthy dogs with atopic dogs, selected bacteria that predominate in healthy dogs. Specifically, among 240 strains isolated from feces of healthy dogs, 184 strains belong to the above-mentioned selected bacteria, and these bacteria were subjected to a systematic classification analysis based on the 16sRNA gene. As a result, 13 species of 4 genera of the genera Bacteroides (Bacteroides), enterococcus (Enterococcus), lactobacillus (Lactobacillus), and Streptococcus (Streptococcus) were identified, and Lactobacillus animals (l.animalis) of the genus Lactobacillus (Lactobacillus) which have not been reported to be involved in the onset of allergy were analyzed.

The present inventors have observed that when lactobacillus animalis is orally administered to an atopic dermatitis model and an allergic asthma model in mice, the effect of suppressing each symptom caused by allergy is observed. And it was known that lactobacillus plantarum has a higher allergy-suppressing effect than lactobacillus johnsonii (l.johnsonii) which has been reported to have an allergy-suppressing effect.

The present invention has been completed based on the above findings.

That is, the present invention relates to the following (1) to (7).

(1) A composition comprises a lactic acid bacterium belonging to Lactobacillus animalis or a treated product of the lactic acid bacterium.

(2) The composition according to the item (1), wherein the lactic acid bacteria are Lactobacillus plantarum strains deposited under the accession number NITE BP-03137, the accession number NITE BP-03138, the accession number NITE BP-03139 and/or the accession number NITE BP-03140.

(3) The lactic acid bacterium or the composition according to the above (1) or (2), which has an antiallergic activity.

(4) The composition according to any one of the above (1) to (3), wherein the composition is a food or beverage composition.

(5) The composition according to any one of the above (1) to (3), wherein the composition is a pharmaceutical composition.

(6) The composition according to any one of the above (1) to (3), wherein the composition is a feed composition.

(7) The composition according to any one of the above (1) to (3), wherein the composition is a sanitary composition.

According to the present invention, a lactic acid bacterium exhibiting an effect of suppressing allergy higher than that of a lactic acid bacterium reported in the past can be provided.

Drawings

Fig. 1 shows the results of analysis using the atopic dermatitis model (1). The number of scratching behaviors per 1 hour of the model mice was determined 4 weeks after the start of transdermal administration of mite antigen (a) and 7 weeks after (B) (n = 8). Data represent mean and error bars represent standard error. * P <0.01.

Fig. 2 shows the analysis result (2) using the atopic dermatitis model. The skin symptoms were scored weekly from the start of transdermal administration of mite antigen to 10 weeks (left panel) (n = 8). Data represent mean and error bars represent standard error. Further, a photograph showing skin symptoms after administration of mite antigen of a model mouse is shown (right panel).

Fig. 3 shows the analysis result using the atopic dermatitis model (3). The results were obtained by measuring the thickness of the back skin every week from the start of transdermal administration of mite antigen to 10 weeks (n = 8). Data represent mean and error bars represent standard error. * P <0.01, P <0.05.

Fig. 4 shows the analysis result using the atopic dermatitis model (4). Is a count of the CD3 present in the auricular lymph nodes collected from model mice the day following the final administration of mite antigen ⁺ CD4 ⁺ T cell (A), CD19 ⁺ IgE ⁺ B cells (B) and CD11c ⁺ CD40 ⁺ Number of dendritic cells (C) (n = 8). Data represent mean and error bars represent standard error. * P<0.01，*P<0.05. Intact (act) is the result of using mice that have not been treated with mites, and Control (Control) is the result of using model mice that have not been administered with lactic acid bacteria (same in the following figures).

Fig. 5 shows the analysis result using the atopic dermatitis model (5). The amount of each cytokine produced in the auricular lymph nodes collected from the model mouse on the next day of the final administration of the mite antigen (A: IL-4, B: IL-9, C: IL-13, D: IL-17, E: TNF α) was measured (n = 8). ND is below the detection limit. Data represent mean and error bars represent standard error. * P <0.01, P <0.05.

Fig. 6 shows the analysis result using the atopic dermatitis model (6). The amounts of various cytokines (A: IL-1. Alpha., B: IL-4, C: IL-5, D: IL-9, E: IL-13, F: IL-17) produced in auricle skin tissues collected from model mice on the day following the final administration of mite antigens were measured (n = 8). Data represent mean and error bars represent standard error. * P <0.01, P <0.05.

Fig. 7 shows the analysis result using the atopic dermatitis model (7). The amount of each cytokine (A: IL-33, B: TNF α, C: TSLP) produced in auricle skin tissue collected from model mice on the day following the final administration of mite antigen was determined (n = 8). Data represent mean and error bars represent standard error. * P <0.05.

Fig. 8 shows the analysis result using the atopic dermatitis model (8). Serum was prepared from blood collected from model mice the next day of final dosing of mite antigen, and the total IgE amount in this serum was determined (n = 8). Error bars indicate standard error.

Fig. 9 shows the analysis result (1) using the allergic asthma model. Is a count of the CD3 present in the pulmonic lymph nodes collected from model mice the day following the final induction of mite antigens ⁺ CD4 ⁺ T cell (A), CD19 ⁺ IgE ⁺ B cells (B) and CD11c ⁺ CD40 ⁺ The number of dendritic cells (C) was counted (n = 8). Data represent mean and error bars represent standard error. * P<0.01，*P<0.05。

Fig. 10 shows the analysis result (2) using the allergic asthma model. The amount of each cytokine produced in the pulmonary lymph nodes collected from the model mice on the next day of final induction of mite antigens (A: IL-4, B: IL-5, C: IL-9, D: IL-13, E: IL-17) was determined (n = 8). ND is below the detection limit. Data represent mean and error bars represent standard error. * P <0.01, P <0.05.

Fig. 11 shows the analysis result (3) using the allergic asthma model. The results were obtained by counting eosinophils (a) and neutrophils (B) in an alveolar lavage fluid collected from a model mouse on the next day of final induction of mite antigens (n = 8). Data represent mean and error bars represent standard error. * P <0.01, P <0.05.

Detailed Description

Embodiment 1 of the present invention is a composition containing a lactic acid bacterium belonging to Lactobacillus animalis (Lactobacillus animalis) or a treated product of the lactic acid bacterium (hereinafter also referred to as "the composition of the present invention"). As the animal lactobacillus used in the embodiment of the present invention, for example, in addition to the species having the gene sequence registered therein with NCBI accession No. NZ _ AYYW00000000.1, the strain deposited at 21.2months (the original deposit) of the national institute of technology and technology Biotechnology center (NPMD) (postal code 292-0818, total Sickle in Kyowa Kagaku K, japan, from 2-5-8) under accession No. NITE P-03137 (identification name: L11-2), deposit No. NITE P-03138 (identification name: L13-1), deposit No. NITE P-03139 (identification name: L41-1) and deposit No. NITE P-03140 (identification name: M08-1) under 2020P-4736 are preferable. It should be noted that, the strains specified by the deposit numbers NITE P-03137, NITE P-03138, NITE P-03139 and NITE P-03140 were subsequently transferred from the original deposit list to the international depository (the issuance date of "proof of deposit" and "proof of survival" at 2021, 3 and 4 days) under the Budapest treaty, and the deposit numbers NITE BP-03137, NITE BP-03138, NITE BP-03139 and NITE BP-03140 were deposited, respectively. The deposited strain may be obtained from the above-mentioned storage agency.

The method for culturing animal lactobacillus is not particularly limited, and any method may be used as long as it is a method generally selected by those skilled in the art as a method for culturing lactic acid bacteria. For example, the culture can be carried out under anaerobic conditions at a culture temperature of 20 to 50 ℃ and preferably 25 to 40 ℃.

The medium for propagation of lactobacillus animalis is not particularly limited, and a medium generally selected by those skilled in the art may be used. Such a medium may be, for example, a medium containing the following components in a composition suitable for the strain: carbon sources (glucose, galactose, mannose, lactose, sucrose, cellobiose, trehalose, etc.), nitrogen sources (ammonia, ammonium sulfate, ammonium chloride, ammonium nitrate, etc.), inorganic salts (sodium chloride, potassium sulfate, magnesium sulfate, calcium chloride, calcium nitrate, etc.), organic components (peptone, yeast extract, meat extract, soybean meal, etc.), and MRS medium, LBS medium, etc. can be preferably used.

The treated microbial cells of the present invention include, for example, cultures and fermentations of microbial cells, and the state of the contained lactic acid bacteria may be either live microbial cells or dead microbial cells. Examples of the treated microbial cell include, but are not limited to, a substance obtained by heating, creaming, drying, freezing, lysing, crushing, extracting lactic acid bacteria, and a supernatant obtained by removing solid components of a crushed microbial cell, a cultured microbial cell, and a fermented product.

The composition of the present invention may contain other substances in addition to lactobacillus animalis or a treated product of the lactobacillus animalis. The other substances are not particularly limited, and include, for example, lactose, glucose, mannitol, sucrose, dextrin, cyclodextrin, starch, cellulose, collagen, citric acid, acetic acid, salt, vitamins, and the like.

The composition of the present invention has an effect of suppressing the onset of allergy, and can be provided, for example, as a food or drink composition, a pharmaceutical composition, a feed composition, a sanitary composition, and the like, depending on the purpose of use, but is not limited to these compositions.

When the composition of the present invention is a pharmaceutical composition, the dosage form is not particularly limited, and examples thereof include tablets, capsules, granules, powders, syrups, liquid preparations, suppositories, and injections. These formulations can be prepared according to conventional methods. In addition, in the case of liquid preparations, it may be dissolved or suspended in water or other suitable solvent at the time of use. The tablets and granules may be coated by a known method. In the case of an injection, the antibody or functional fragment thereof of the present invention may be prepared by dissolving in water, and if necessary, may be dissolved in a physiological saline or glucose solution, and a buffer or a preservative may be added.

When the composition of the present invention is provided as a food or beverage composition, the form thereof is not particularly limited, and examples thereof include beverages such as soft drinks and nutritional drinks, desserts such as candies, chewing gums, jellies, creams and ice creams, dairy products such as milk drinks, fermented milks, beverage yogurts and butters, and other supplements.

The form of the composition of the present invention is not particularly limited when it is provided as a sanitary composition, and examples thereof include toothpaste, skin cream, soap, shampoo, cosmetic, aerosol, spray, and coating agent, and sanitary compositions for non-human animals.

In addition, the compositions of the present invention may be feed compositions ingestible by non-human animals and pharmaceutical compositions for animals. The animal feed as referred to herein includes, in addition to so-called food taken as a nutrient source required for animals, supplements for animals to be administered as hobbies for animals, and the like.

Embodiment 2 of the present invention is a method for preventing allergic attack (hereinafter also referred to as "the method for preventing of the present invention") comprising administering the pharmaceutical composition of the present invention to a subject.

Here, "prevention" refers to treatment with the purpose of preventing the onset of allergy in advance.

The object of the prophylactic method of the present invention is not particularly limited, and may be any animal classified as a mammal, for example, a pet such as a dog, cat, or rabbit, a livestock animal such as a cow, pig, sheep, or horse, or the like, in addition to a human. Particularly preferred "mammals" are humans and dogs.

Where the specification is to be interpreted to include words "a", "an" and "the" in the singular, the singular and the plural are included unless the context clearly dictates otherwise.

The present invention will be further described with reference to the following examples, which are merely illustrative of embodiments of the present invention and do not limit the scope of the present invention.

Examples

1. Experimental methods

1-1 isolation of lactic acid bacteria from feces and systematic Classification

Among 240 strains of bacteria isolated from feces of healthy dogs (16 dogs), 184 strains that are superior to the intestinal flora of atopic dogs in the intestinal flora of healthy dogs were selected and analyzed by systematic classification. Specifically, feces collected from dogs were subjected to resting evening-out culture at 37 ℃ under anaerobic conditions using MRS liquid medium or LBS liquid medium. After culturing, isolation of bacteria was performed using MRS or LBS plate medium. Purification was performed a minimum of 3 times. Systematic classification of bacteria was based on 16S rRNA sequencing. As a result, 13 species of 4 genera of bacteroides, enterococcus, lactobacillus, and streptococcus were identified, and lactobacillus animalis (l.animalis) of lactobacillus which has not been reported to be involved in the onset of allergy was selected as an analysis target. As a positive control in this example, lactobacillus johnsonii (l.johnsonii) which is considered to be involved in the onset of allergy was used. The lactobacillus animalis used in this example was a strain deposited under the accession numbers NITE BP-03137, NITE BP-03138, NITE BP-03139 and NITE BP-03140, and the number of bacteria was 1:1:1:1, in a mixture.

1-2 analysis of disease model mice

All animal experiments used in this example were carried out with the approval of the animal experiments committee of the university of hessian.

1-2-1 model of atopic dermatitis

The experiment was performed using 6-week-old female NC/Nga mice (Charles River Laboratories Japan). After 1 week of acclimation, 0.2ml (10 ml) of Lactobacillus plantarum or Lactobacillus johnsonii was orally administered to each mouse ⁹ ) After 2 weeks, sensitization with mite antigens (Dermatophagoides farinae) was initiated. The skin of the neck and back was shaved before sensitization with mite antigens, and after 10 tape strippings on the neck and back, 30. Mu.l (0.25 mg/ml) of mite suspension was transdermally administered to 10. Mu.l each of both auricles using a pipette. Administration of mite antigen was performed 2 times a week for 12 weeks, and monitoring of itching behavior, scoring of skin symptoms, and thickness measurement of back skin were performed weekly.

The pruritus behavior was monitored by taking the behavior of biting or scratching the mite antigen-coated site (auricle and back skin) with hind limb, fore limb or tongue as 1 pruritus behavior among the behaviors of the mouse recorded with a video camera, and recording the number of times of pruritus behaviors within 60 minutes.

Skin observation was performed by scoring scabbing, ulcer formation, and redness of the auricle and back skin (the degree of symptoms was scored on a scale of 0 to 4), and the cumulative value was evaluated as a cumulative score.

The thickness of the dorsal skin was measured 1 time per week using a vernier caliper.

On the day following the final administration of mite antigen, blood was collected from the mice under isoflurane inhalation anesthesia, and thereafter, euthanasia was performed to sample the auricular lymph nodes and the auricular skin.

After separating serum from blood, the total IgE content in blood was quantified by ELISA.

The auricular lymph node is obtained by separating single cells and separating the cells based on cell surface antigens by a flow cytometry method. Helper T cells (CD 3) in the obtained cells ⁺ CD4 ⁺ T cells) were cultured in the presence of anti-CD 3 antibody and anti-CD 28 antibody (VERITAS corporation) for 24 to 96 hours, and then the production amounts of various cytokines in the culture supernatants were measured by ELISA.

Collected auricle skin was frozen with liquid nitrogen, and the amounts of various cytokines in supernatants obtained by homogenization in 500. Mu.l of PBS using an electric homogenizer were measured by ELISA method.

1-2-2 model of allergic asthma

The experiment was performed using 6-week-old female BALB/c mice (Charles River Laboratories Japan). After 1 week of acclimation, 0.2ml (10 ml) of Lactobacillus plantarum or Lactobacillus johnsonii was orally administered to each mouse ⁹ ) After 2 weeks, sensitization with mite antigens (Dermatophagoides farinae) was initiated. The mite antigen was sensitized by nasal administration of 30. Mu.l (1 mg/ml) of mite suspension under isoflurane inhalation anesthesia using a pipette. Administration of mite antigen was performed 1 time per week for 3 consecutive weeks. In the same way, 5. Mu.l (0.2 mg/ml) of mite suspension was induced by nasal administration using a pipette under isoflurane inhalation anesthesia for 3 consecutive days at week 4. On the next day of final induction of mite antigens, blood was collected from mice under isoflurane inhalation anesthesia, and then euthanized, and the lavage fluid from the pulmonary lymph nodes and pulmonary alveoli was sampled.

The alveolar lavage fluid was used to count the numbers of eosinophils (eosinophil) and neutrophils (neutrophil) in the lavage fluid.

After single cells were isolated, the lung lymph nodes were separated by flow cytometry to obtain cells based on cell surface antigen isolation. Helper T cells (CD 3) in the obtained cells ⁺ CD4 ⁺ T cells) were cultured in the presence of anti-CD 3 antibody and anti-CD 28 antibody for 24 to 96 hours, and then the production amounts of various cytokines in the culture supernatants were measured by ELISA.

1-3 statistical analysis

For the data obtained, the mean and standard error of each group were calculated, and multiple comparative tests were performed in all groups for each experiment. In the multiple comparison test, a variance test is performed by the Bartlett method or the like, and in the case of variance, the Dunnett's test is employed. For each examination item, the presence or absence of a statistically significant difference between the groups was analyzed at a significance level of 5% and 1%.

2. Results

2-1 model of atopic dermatitis

Atopic dermatitis is a pathological state in which symptoms worsen due to the alternation of itching and skin inflammation. Therefore, the effect of lactic acid bacteria on itch was investigated by measuring the itch behavior of the mouse model every 1 hour immediately after 1-time weekly administration of mite antigen.

According to the results of the analysis of the mouse model in which atopic dermatitis was induced by administration of mite antigen, it was considered that the number of scratching behaviors was significantly reduced in the mice given with lactobacillus animalis and the mice given with lactobacillus johnsonii compared to the control mice (no administration of lactic acid bacteria) (fig. 1A and B).

In addition, fig. 2 is a result of scoring atopic skin symptoms during administration of mite antigen. The atopic symptom expression was greatly affected by individuals, and although no statistically significant difference was found, the degree of reduction of skin symptoms was high in the lactobacillus-administered animal group and the lactobacillus johnsonii-administered group as compared with the control group. In addition, the reduction of symptoms in the lactobacillus plantarum administered group was greater when compared with the lactobacillus johnsonii administered group.

As the symptoms of atopic dermatitis worsen, epidermal thickening and cell infiltration occur, and the thickness of the skin increases. Therefore, the thickness of the dorsal skin of the model mouse was measured. As a result, the skin thickness was significantly reduced in the lactobacillus plantarum administration group and the lactobacillus johnsonii administration group, compared to the control group. Among them, the reduction in thickness of the lactobacillus-administered group of animals was observed to have a statistical significance, and even compared with the lactobacillus johnsonii-administered group, there was a significant reduction (fig. 3).

After final dissection, auricle lymph nodes were collected, and allergy-associated immune cells (helper T cells (CD 3)) in the lymph nodes were counted by flow cytometry ⁺ CD4 ⁺ T cells), igE positive B cells (CD 19) ⁺ IgE ⁺ B cells) and activated dendritic cells (CD 11 c) ⁺ CD40 ⁺ Dendritic cells)). As a result, it was found that the number of cells was reduced in the group to which Lactobacillus animalis was administered and the group to which Lactobacillus johnsonii was administered, among all the cells. In particular, significant reduction was observed in helper T cells and IgE positive B cells compared to the control group, wherein the reduction was significant in the lactobacillus-administered animal group (fig. 4).

Next, helper T cells collected from the auricular lymph nodes were cultured in the presence of CD3 and CD28 antibodies, and the amounts of inflammatory cytokines (IL-4, IL-9, IL-13, IL-17, and TNF. Alpha.) produced were measured. As a result, the production amount of inflammatory cytokines was significantly reduced in both the lactobacillus-administered animal group and the lactobacillus johnsonii-administered group, as compared with the control group (fig. 5). In particular, a significant reduction in the amount of inflammatory cytokine production was observed in the group administered with Lactobacillus plantarum compared to the group administered with Lactobacillus johnsonii.

As a result of measuring the amounts of inflammatory cytokines (IL-1. Alpha., IL-4, IL-5, IL-9, IL-13, and IL-17) in auricular skin tissues, a significant decrease in the amounts of cytokines was observed in the Lactobacillus animalis-administered group and the Lactobacillus johnsonii-administered group, as in the case of the auricular lymph nodes (FIG. 6). Fig. 7 shows the results of quantifying the amounts of cytokines (IL-33, TNF α, and TSLP (thymic stromal lymphopoietin)) related to itching in the skin tissues of the auricles. Although no significant reduction in TSLP was observed, significant reduction in the amount of keratinocyte-derived cytokines such as IL-33 and TNF α was observed in the groups administered with Lactobacillus animalis and Lactobacillus johnsonii compared with the control group.

Next, the amount of total IgE in the serum prepared from the model mouse was determined. As a result, a significant decrease in the amount of total IgE in serum was observed in the lactobacillus-animalis-administered group and the lactobacillus johnsonii-administered group (fig. 8).

2-2 model of allergic asthma

After final dissection of the allergic asthma model mice, the pulmonary lymph nodes were collected, and the numbers of allergy-associated immune cells (helper T cells, igE-positive B cells, and activated dendritic cells) in the lymph nodes were analyzed by flow cytometry in the same manner as in the atopic dermatitis model. As a result, a significant decrease in the number of each cell in the pulmonary lymph node of the lactobacillus-administered animal group and the lactobacillus johnsonii-administered group was observed for all the allergy-related immune cells. In particular, the reduction in lactobacillus administration group was significant (fig. 9).

Next, helper T cells collected from the pulmonary lymph nodes are cultured in the presence of CD3 and CD28 antibodies, and the production amounts of inflammatory cytokines (IL-4, IL-5, IL-9, IL-13, and IL-17) are measured. As a result, the production amount of inflammatory cytokines was significantly reduced in both the lactobacillus-administered animal group and the lactobacillus johnsonii-administered group, as compared with the control group (fig. 10). In particular, a significant reduction in the amount of inflammatory cytokine production was observed in the group administered with Lactobacillus plantarum compared to the group administered with Lactobacillus johnsonii.

The allergic asthma model mice were finally dissected by washing the lungs with PBS, and the numbers of eosinophils and neutrophils in the wash (alveolar wash, BALF) were counted using a flow cytometer (fig. 11). For any of the cell species, a decrease in the number of cells was observed in both the lactobacillus plantarum administration group and the lactobacillus johnsonii administration group, and particularly, a significant decrease in the number of cells was observed in the lactobacillus plantarum administration group.

Industrial applicability

The present invention provides a composition exhibiting an effect of suppressing allergic attacks, which is expected to be used in the field of food and drink production in addition to the fields of medicine and veterinary medicine.

Deposit number

Deposit number NITE BP-03137

Deposit number NITE BP-03138

Deposit number NITE BP-03139

Deposit number NITE BP-03140.

Claims (7)

1. A composition comprises a lactic acid bacterium belonging to Lactobacillus animalis or a treated product of the lactic acid bacterium.

2. The composition according to claim 1, wherein the lactic acid bacteria are lactobacillus plantarum strains deposited under deposit number NITE BP-03137, deposit number NITE BP-03138, deposit number NITE BP-03139 and/or deposit number NITE BP-03140.

3. The lactic acid bacterium or the composition according to claim 1 or 2, which has an anti-allergic activity.

4. The composition according to any one of claims 1 to 3, wherein the composition is a food or beverage composition.

5. The composition according to any one of claims 1 to 3, wherein the composition is a pharmaceutical composition.

6. The composition according to any one of claims 1 to 3, wherein the composition is a feed composition.

7. The composition according to any one of claims 1 to 3, wherein the composition is a hygiene composition.